About the Company
Laura Elizabeth Niklason is a physician, professor and internationally recognized researcher in vascular and lung tissue engineering. She is the Nicholas M. Greene Professor of Anesthesiology and Biomedical Engineering at Yale University and co-founder, chief executive officer and president of Humacyte, a regenerative medicine company developing bioengineered human tissues. Her work on lab-grown lungs was recognized as one of the top 50 most important inventions of 2010 by Time magazine. Niklason was included on Fortune’s “Digital Health Care Leaders” list in 2017 for her work in regenerative medicine. Niklason was inducted into the National Academy of Inventors in 2014. In 2015, she was elected to the National Academy of Medicine. In 2020, Niklason was elected a member of the National Academy of Engineering for cardiovascular tissue engineering, lung regeneration, and biomedical imaging. She holds more than 30 issued or pending patents in the United States.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Humacyte, Inc.
Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a ...
Humacyte, Inc. to Release First Quarter 2025 Financial Results ... - Nasdaq
Humacyte, Inc. will announce its financial results for the first quarter of 2025 on May 13, 2025, during a conference call at 8:30 a.m. ET, where management will provide updates on corporate and ...
Humacyte, Inc. (NASDAQ:HUMA) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 11, 2025 Humacyte, Inc. misses on earnings expectations. Reported EPS is $-0.24 EPS, ...
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
In the latest trading session, Humacyte, Inc. (HUMA) closed at $2.53, marking a -5.24% move from the previous day. This move lagged the S&P 500's daily gain of 0.4%. On the other hand, the Dow ...
Humacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to Note
Humacyte, Inc. (HUMA) closed the most recent trading day at $1.48, moving +0.68% from the previous trading session. The stock lagged the S&P 500's daily gain of 2.03%. Meanwhile, the Dow gained 1. ...
Humacyte, Inc. Announces Pricing of Public Offering of Common Sto
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Humacyte Announces Addition of Chief Commercial Officer and ... - Nasdaq
--Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced advancements in its commercial ...
HUMAW Humacyte, Inc. WT EXP - Seeking Alpha
A high-level overview of Humacyte, Inc. WT EXP (HUMAW) stock. View (HUMAW) real-time stock price, chart, news, analysis, analyst reviews and more.
Humacyte, partner for IPO name nominees for board as IPO nears
Laura E. Niklason, M.D., Ph.D. – Dr. Niklason is the founder of Humacyte and has served as President and Chief Executive Officer since November 2020 and as a member of the Humacyte Board since ...
Humacyte, Inc. Announces Pricing of Public Offering of Common Stock
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Similar Companies
Loading the latest forecasts...